Sale disclosed
Christopher John Kenney
Chief Medical Officer
Common Shares
- Reported value
- $383.15K
- Reported price
- $60.1673 / share
Loading data…Scanning SEC filings…Checking Congress reports…Following the signal…
Xenon Pharmaceuticals Inc.
Last 30 daysInsiders bought $1.68M · 2 buyers, led by Ian Mortimer (CEO) with $1.12M. No qualifying insider sales.
Chief Medical Officer
Common Shares
Chief Medical Officer
Common Shares
Director
Common Shares
Director
Common Shares
Director
Common Shares
| Reporting insider | Security / transaction | Amount / price | Value | Traded / disclosed | Source |
|---|---|---|---|---|---|
| Chief Medical Officer | Common SharesSale10b5-12 trades | 7,068avg $60.25 / share | $425.83K | Aug 28Filed Aug 31 · 3d later | 2 filings
|
| Director | Common SharesSale | 10,000$64.06 / share | $640.55K | Aug 11Filed Aug 13 · 2d later | SEC filing |
| Director | Common SharesSale10b5-1 | 1,322$53.14 / share | $70.25K | Jun 5Filed Jun 8 · 3d later | SEC filing |
| Director | Common SharesSale10b5-1 | 1,190$53.14 / share | $63.24K | Jun 5Filed Jun 8 · 3d later | SEC filing |
This reflects the filings imported so far, not a complete trading history.
$1,681,140 of common-equity purchase value after transaction-age decay across 180 days.
2 distinct reporting-owner group(s). Joint rows count once; identity is not proof of discretion.
Qualifying common-equity P acquisition; no disclosed plan, exercise or excluded purchase context detected.
Qualifying common-equity P acquisition; no disclosed plan, exercise or excluded purchase context detected.
2 buying groups inside 30 transaction-date days, public by the snapshot cutoff.
At least one row increased reported same-security holdings by 10% or established a new reported position; indirect interests may overlap.
This score describes qualifying insider purchases at issuer level. Read the methodology
Open a transaction's SEC filing for the primary evidence. A code P may describe an open-market or private purchase; classification is not proof of intent.
Insider activity can have many explanations. Signal Strength is not a probability of profit or a recommendation to trade.